QNRX · Quoin Pharmaceuticals Ltd. American Depositary Shares
View on chartInsiders & Stakes
| Gordon Dunn Chief Financial Officer | ▲ Buy | Open Market | 151,077 Shares held | 12/23/2024 | View profile |
| Dennis Langer Director | ▲ Buy | Grant | 56,243 Shares held | 8/27/2026 | View profile |
| Anthony James Culverwell Director | ▲ Buy | Open Market | 40,364 Shares held | 8/31/2026 | View profile |
| Michael Myers Chief Executive Officer | ▲ Buy | Open Market | 37,713 Shares held | 8/31/2026 | View profile |
| Denise P. Carter Chief Operating Officer | ▲ Buy | Open Market | 37,709 Shares held | 8/31/2026 | View profile |
| Lawlor Sally Bridget Chief Financial Officer | ▲ Buy | Open Market | 10,684 Shares held | 8/31/2026 | View profile |
Transaction History
| Denise P. Carter | ▲ Buy | Open Market | 20,490 | $100K | 8/31/2026 |
| Michael Myers | ▲ Buy | Open Market | 20,490 | $100K | 8/31/2026 |
| Lawlor Sally Bridget | ▲ Buy | Open Market | 10,244 | $50K | 8/31/2026 |
| Anthony James Culverwell | ▲ Buy | Open Market | 6,146 | $30K | 8/31/2026 |
| Dennis Langer | ▲ Buy | Grant | 34,534 | $178K | 8/27/2026 |
| Anthony James Culverwell | ▲ Buy | Grant | 31,352 | $161K | 8/27/2026 |
| Dennis Langer | ▲ Buy | Open Market | 15,152 | $129K | 10/14/2025 |
| Gordon Dunn | ▲ Buy | Open Market | 122,221 | $55K | 12/23/2024 |
| Anthony James Culverwell | ▲ Buy | Open Market | 100,000 | $45K | 12/23/2024 |
| Denise P. Carter | ▲ Buy | Open Market | 555,556 | $250K | 12/23/2024 |
| Michael Myers | ▲ Buy | Open Market | 555,556 | $250K | 12/23/2024 |
| Gordon Dunn | ▲ Buy | Open Market | 10,000 | $9K | 9/10/2024 |
| Gordon Dunn | ▲ Buy | Open Market | 10,000 | $7K | 9/10/2024 |
| Gordon Dunn | ▲ Buy | Open Market | 4,000 | $3K | 9/9/2024 |
| Gordon Dunn | ▲ Buy | Open Market | 856 | $685 | 9/9/2024 |
| Gordon Dunn | ▲ Buy | Open Market | 4,000 | $3K | 9/9/2024 |
| Denise P. Carter | ▲ Buy | Open Market | 8,825 | $7K | 9/4/2024 |
| Denise P. Carter | ▲ Buy | Open Market | 22,988 | $18K | 9/4/2024 |
| Michael Myers | ▲ Buy | Open Market | 5,322 | $3K | 9/4/2024 |
| Michael Myers | ▲ Buy | Open Market | 8,200 | $6K | 9/4/2024 |
| Michael Myers | ▲ Buy | Open Market | 23,572 | $19K | 9/4/2024 |
| Denise P. Carter | ▲ Buy | Open Market | 1,822 | $1K | 9/3/2024 |
| Denise P. Carter | ▲ Buy | Open Market | 4,100 | $3K | 9/3/2024 |
| Michael Myers | ▲ Buy | Open Market | 800 | $495 | 9/3/2024 |
| Dennis Langer | ▼ Sell | Open Market | 297 | $217 | 6/7/2024 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
QNRX: Manuscript Acceptance for QRX003 in Dermatology
Quoin Pharmaceuticals announced that a manuscript on its drug QRX003 for Netherton syndrome has been accepted for publication in Dermatology and Therapy. The paper includes a pediatric compassionate‑use case report, highlighting early clinical experience. Acceptance may support the company’s ongoing development and regulatory discussions. The news comes as the stock trades near its 14‑day support level.
QNRX: Manuscript Acceptance for QRX003 in Dermatology. Quoin Pharmaceuticals announced that a manuscript on its drug QRX003 for Netherton syndrome has been accepted for publication in Dermatology and Therapy. The paper includes a pediatric compassionate‑use case report, highlighting early clinical experience. Acceptance may support the company’s ongoing development and regulatory discussions. The news comes as the stock trades near its 14‑day support level.